CD8þPD-1–ILT2þ T cells are an intratumoral cytotoxic population selectively inhibited by the immune-checkpoint HLA-G

59Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Only some cancer patients respond to the immune-checkpoint inhibitors being used in the clinic, and other therapeutic targets are sought. Here, we investigated the HLA-G/ILT2 checkpoint in clear-cell renal-cell carcinoma (ccRCC) patients and focused on tumor-infiltrating CD8þ T lymphocytes (TIL) expressing the HLA-G receptor ILT2. Using transcriptomics and flow cytometry, we characterized both peripheral blood and tumor-infiltrating CD8þILT2þ T cells from cancer patients as late-differentiated CD27–CD28–CD57þ cytotoxic effectors. We observed a clear dichotomy between CD8þILT2þ and CD8þPD-1þ TIL subsets. These subsets, which were sometimes present at comparable frequencies in TIL populations, barely overlapped phenotypically and were distinguished by expression of exclusive sets of surface molecules that included checkpoint molecules and activating and inhibitory receptors. CD8þILT2þ TILs displayed a more mature phenotype and higher expression of cytotoxic molecules. In ex vivo functional experiments with both peripheral blood T cells and TILs, CD8þILT2þ T cells displayed significantly higher cytotoxicity and IFNg production than their ILT2– (peripheral blood mononuclear cells, PBMC) and PD-1þ (TILs) counterparts. HLA-G expression by target cells specifically inhibited CD8þILT2þ T-cell cytotoxicity, but not that of their CD8þILT2–(PBMC) or CD8þPD-1þ (TIL) counterparts, an effect counteracted by blocking the HLA-G/ILT2 interaction. CD8þILT2þ TILs may therefore constitute an untapped reservoir of fully differentiated cytotoxic T cells within the tumor microenvironment, independent of the PD1þ TILs targeted by immune therapies, and specifically inhibited by HLA-G. These results emphasize the potential of therapeutically targeting the HLA-G/ILT2 checkpoint in HLA-Gþ tumors, either concomitantly with anti–PD-1/PD-L1 or in cases of nonresponsiveness to anti–PD-1/PD-L1.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Dumont, C., Jacquier, A., Verine, J., Noel, F., Goujon, A., Wu, C. L., … LeMaoult, J. (2019). CD8þPD-1–ILT2þ T cells are an intratumoral cytotoxic population selectively inhibited by the immune-checkpoint HLA-G. Cancer Immunology Research, 7(10), 1619–1632. https://doi.org/10.1158/2326-6066.CIR-18-0764

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 22

67%

Researcher 7

21%

Professor / Associate Prof. 4

12%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 15

48%

Immunology and Microbiology 8

26%

Medicine and Dentistry 6

19%

Computer Science 2

6%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free